Correction: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

CONSIT TEAM thanks Siranoush Manokian, Bernard Peissel, Elisa Cattaneo, and Daniela Zaffaroni of Fondazione IRCCS Istituto Nazionale Tumori (INT); Milan, Bernardo Bonanni, Monica Barile, and Irene Feroce of the Istituto Europeo di Oncologia (IEO); Milan, Alessandra Viel, and Riccardo Dolcetti of the Centro di Riferimento Oncologico (CRO) IRCCS; Aviano (PN) and Liliana Varesco of IRCCS AOU San Martino—IST Istituto Nazionale per la Ricerca sul Cancro of Genoa; Laura Papi and Maurizio Genuardi of University of Florence, Florence; Laura Ottini and Giuseppe Giannini of “La Sapienza” University, Rome; Antonella Savarese and Aline Martayan of Istituto Nazionale Tumori Regina Elena (IRE), Rome; and Loris Bernard, Sara Volorio, Valeria Pensotti, and all the personnel of the CGT-lab at IFOM-IEO Campus, Milan, Italy.

CONSIT TEAM was funded by grants from Fondazione Italiana per la Ricerca sul Cancro (Special Project “Hereditary tumors”), Italian Association for Cancer Research (AIRC, IG 8713), Italian Ministry of Health (Extraordinary National Cancer Program 2006, “Alleanza contro il Cancro” and “Progetto Tumori Femminili”), Italian Ministry of Education, University and Research (Prin 2008), and by funds from Italian citizens who allocated the 5 × 1,000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects “5 × 1,000”). City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry, supported in part by Award Number RC4CA153828 (PI: J.N. Weitzel) from the National Cancer Institute and the Office of the Director, NIH.